An artificial-intelligence approach created at Carolina could help bring new drugs to patients quicker.
An artificial-intelligence approach created at the University of North Carolina at Chapel Hill Eshelman School of Pharmacy can teach itself to design new drug molecules from scratch and has the potential to dramatically accelerate the design of new drug candidates.
The system is called Reinforcement Learning for Structural Evolution, known as ReLeaSE, and is an algorithm and computer program that comprises two neural networks which can be thought of as a teacher and a student. The teacher knows the syntax and linguistic rules behind the vocabulary of chemical structures for about 1.7 million known biologically active molecules. By working with the teacher, the student learns over time and becomes better at proposing molecules that are likely to be useful as new medicines.
Alexander Tropsha, Olexandr Isayev and Mariya Popova, all of the UNC Eshelman School of Pharmacy, are the creators of ReLeaSE. The University has applied for a patent for the technology, and the team published a proof-of-concept study in the journal Science Advances last week.
“If we compare this process to learning a language, then after the student learns the molecular alphabet and the rules of the language, they can create new ‘words,’ or molecules,” said Tropsha. “If the new molecule is realistic and has the desired effect, the teacher approves. If not, the teacher disapproves, forcing the student to avoid bad molecules and create good ones.”
ReLeaSE is a powerful innovation to virtual screening, the computational method widely used by the pharmaceutical industry to identify viable drug candidates. Virtual screening allows scientists to evaluate existing large chemical libraries, but the method only works for known chemicals. ReLeASE has the unique ability to create and evaluate new molecules.
“A scientist using virtual screening is like a customer ordering in a restaurant. What can be ordered is usually limited by the menu,” said Isayev. “We want to give scientists a grocery store and a personal chef who can create any dish they want.”
The team has used ReLeaSE to generate molecules with properties that they specified, such as desired bioactivity and safety profiles.The team used the ReLeaSE method to design molecules with customized physical properties, such as melting point and solubility in water, and to design new compounds with inhibitory activity against an enzyme that is associated with leukemia.
“The ability of the algorithm to design new, and therefore immediately patentable, chemical entities with specific biological activities and optimal safety profiles should be highly attractive to an industry that is constantly searching for new approaches to shorten the time it takes to bring a new drug candidate to clinical trials,” said Tropsha.
Receive an email update when we add a new DRUG DESIGN article.
The Latest on: Drug design
via Google News
The Latest on: Drug design
- Demi Lovato's new man has a controversial, drug-inspired clothing line on November 7, 2018 at 1:51 pm
His name is Henry Levy (although he often goes by Henri Alexander) and is the 27-year-old fashion designer behind Enfants Riches Déprimés (French for “Depressed Rich Kids”). Although Levy is currently ... […]
- 'Cannabis', £15,000 and designer clothes seized in Norton on November 6, 2018 at 11:00 pm
A DRUGS raid has seen around £15,000 in cash, a haul of designer clothes and suspected cannabis seized by police. Two men and two women have arrested in connection with a drugs warrant executed at a p... […]
- Drug design: Clues for drugging the 'undruggable' on November 5, 2018 at 4:52 pm
Scientists have shown how thalidomide analogs mediate degradation of many more proteins than previously anticipated. These proteins -- zinc finger transcription factors -- play a role in cancer and de... […]
- US FDA issues draft norms on transdermal & topical delivery systems for ANDAs, recommends single-period, two-treatment-per-subject design on November 4, 2018 at 6:30 pm
The US FDA has issued draft norms on transdermal and topical delivery systems for ANDAs (abbreviated new drug application). The regulatory authority recommends single-period, two- treatment-per-subjec... […]
- FDA Blasts Data, Trial Design For Alkermes Depression Drug on October 30, 2018 at 9:44 am
The FDA this morning has issued a scathing review of an experimental drug that could be, if the agency ends up approving it next year, a new option for the millions of Americans who struggle with depr... […]
- Variant Pharmaceuticals Submits Application for U... on October 30, 2018 at 4:08 am
WESTON, Fla., Oct. 30, 2018 /PRNewswire/ -- Variant Pharmaceuticals, Inc. (Variant), a clinical stage orphan drug company developing first-in-class drugs for patients with rare diseases, announced tod... […]
- Cyrus Biotechnology and OpenEye Scientific Software Announce Collaboration and Cheminformatics Integration to Expedite New Drug Design and Development with Cyrus Bench Platform on October 30, 2018 at 2:30 am
SEATTLE--(BUSINESS WIRE)--Cyrus Biotechnology, Inc., a Seattle-based biotech software company commercializing Rosetta, an advanced protein design platform, announced today that through a collaboration ... […]
- FDA Releases Draft Guidances to Promote Clinical Trial Design Efficiency on October 17, 2018 at 8:59 am
On September 28, 2018, the U.S. Food and Drug Administration (FDA) released two draft guidances for industry. The purpose, according to FDA Commissioner Scott Gottlieb, M.D., is to modernize the appro... […]
- Artificial intelligence to improve drug combination design and personalized medicine on September 24, 2018 at 11:25 pm
A new auto-commentary published in SLAS Technology looks at how an emerging area of artificial intelligence, specifically the analysis of small systems-of-interest specific datasets, can be used to im... […]
via Bing News